Grifols (GRFS) Non Operating Income (2011 - 2023)
Grifols (GRFS) reported Non Operating Income of $618082.3 for Q4 2023, up 36.77% on a YoY basis from $451909.4 in Q4 2022, and up 36.77% quarter-over-quarter from $451909.4 in Q4 2022.
Grifols (GRFS) Non Operating Income (2011 - 2023) Analysis & Trends
Grifols has reported Non Operating Income for 11 years, with the latest figure at $618082.3 in Q4 2023.
- For the quarter ending Q4 2023, Non Operating Income rose 36.77% year-over-year to $618082.3; the trailing twelve-month figure through Dec 2023 stood at -$311.3 million (up 23.21% YoY), and the FY2025 full-year result was -$731.0 million, up 8.54% from the prior year.
- Non Operating Income for Q4 2023 stood at $618082.3, up from $451909.4 in the prior quarter.
- The five-year high for Non Operating Income was $618082.3 in Q4 2023, with the low at -$293.8 million in Q4 2019.
- Historically, Non Operating Income has averaged -$80.9 million across 4 years, with a median of -$18.6 million in 2020.
- Annual changes were most pronounced in 2019 — Non Operating Income slumped 42.72% — and 2020, when it surged 80.1%.
- Grifols' Non Operating Income stood at -$293.8 million in 2019, then jumped by 93.67% to -$18.6 million in 2020, then jumped by 102.43% to $451909.4 in 2022, then surged by 36.77% to $618082.3 in 2023.
- The last three Non Operating Income figures came in at $618082.3 (Q4 2023), $451909.4 (Q4 2022), and -$18.6 million (Q1 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 195.49 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -65.00 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -294.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -2.31 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -32.00 Mn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 618,082.29 |
| Dec 31, 2022 | 451,909.39 |
| Mar 31, 2020 | -18.60 Mn |
| Dec 31, 2019 | -293.75 Mn |
| Mar 31, 2019 | -93.45 Mn |
| Dec 31, 2018 | -205.83 Mn |
| Jun 30, 2018 | 47.30 Mn |
| Mar 31, 2018 | -78.08 Mn |
| Dec 31, 2017 | -242.34 Mn |
| Jun 30, 2017 | 89.46 Mn |
| Mar 31, 2017 | -70.56 Mn |
| Dec 31, 2016 | -54.20 Mn |
| Sep 30, 2016 | 66.11 Mn |
| Jun 30, 2016 | 62.82 Mn |
| Mar 31, 2016 | -75.63 Mn |
| Dec 31, 2015 | 62.20 Mn |
| Sep 30, 2015 | 69.40 Mn |
| Jun 30, 2015 | 67.39 Mn |
| Mar 31, 2015 | 83.89 Mn |
| Sep 30, 2013 | 80.06 Mn |